Google
×
We're Horizon, a global biotechnology company driven by a simple idea: we believe that science and compassion must work together to transform lives.
INVESTOR RELATIONS CONTACTS ; Dan Trolio Executive Vice President & CFO (860) 674-9977 dtrolio@horizontechfinance.com. ICR Group Garrett Edson Managing Director
Missing: hznp | Show results with:hznp
Amgen Investor Presentation December 2023 1.8 MB. 10.31.2023. Q3 2023 Earnings Presentation 1.8 MB. 10.24.2023. Hematology/Oncology Update ESMO Presentation 5.7 ...
... ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF ... HZNP. The Nasdaq Global Select Market. Securities ... investor is treated as a United States shareholder ...
People also ask
Aug 8, 2023 · This earnings press release, investor deck and the related Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 are publicly ...
Jul 17, 2023 · Investor Relations: Tina Ventura Senior Vice President, Chief Investor Relations Officer Investor-relations@horizontherapeutics.com. U.S. ...
The Company markets 11 medicines through its orphan, rheumatology and primary care business units. Visit website. REPORT RATINGS. 4.8 / 5.0 (62). Horizon Pharma ...
... shares are admitted to trading on Nasdaq under the ticker "HZNP". ... Investor Relations, by email to ir@horizontherapeutics.com. ... financial-information/sec ...
May 3, 2023 · ... HZNP) today announced first-quarter 2023 financial results. “We ... Chief Investor Relations Officer, Corporate Affairs & Chief Communications ...
... (HZNP) CEO Tim Walbert on Q3 2019 Results - Earnings Call Transcript · SA TranscriptsWed, Nov. 06, 2019. Horizon Pharma plc (HZNP) Investor Presentation - ...
Missing: relations | Show results with:relations